Filtered By:
Condition: Autoimmune Disease
Cancer: Cancer
This page shows you your search results in order of date. This is page number 2.
Order by Relevance | Date
Total 79 results found since Jan 2013.
U.S. FDA Approves TECVAYLI ™ (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
HORSHAM, Pa., October 25, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) approved TECVAYLI™ (teclistamab-cqyv) for the treatment of adult patients with relapsed or refractory multiple myeloma, who previously received four or more prior lines of therapy, including a proteasome inhibitor, immunomodulatory drug and anti-CD38 monoclonal antibody.1 TECVAYLI™ is a first-in-class, bispecific T-cell engager antibody that is administered as a subcutaneous treatment.1 This off-the-shelf (or ready to use) therapy uses innovative science to ac...
Source: Johnson and Johnson - October 25, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
A network-based approach for isolating the chronic inflammation gene signatures underlying complex diseases towards finding new treatment opportunities
Complex diseases are associated with a wide range of cellular, physiological, and clinical phenotypes. To advance our understanding of disease mechanisms and our ability to treat these diseases, it is critical to delineate the molecular basis and therapeutic avenues of specific disease phenotypes, especially those that are associated with multiple diseases. Inflammatory processes constitute one such prominent phenotype, being involved in a wide range of health problems including ischemic heart disease, stroke, cancer, diabetes mellitus, chronic kidney disease, non-alcoholic fatty liver disease, and autoimmune and neurodege...
Source: Frontiers in Pharmacology - October 12, 2022 Category: Drugs & Pharmacology Source Type: research
Science Saturday: Do environmental exposures contribute to human diseases?
An accumulation of environmental chemicals, pollutants, microbes, and particulates may be living inside each of us — acquired from the air we breathe, the food we eat, products we touch, and the water we drink. These sometimes-harmful exposures can potentially interact with our genes to fuel diseases, including cancer, cardiovascular disease, respiratory illnesses, autoimmune diseases, and stroke. Research sh ows environmental factors are associated with more than 80% of human diseases and nearly 1 in 6 deaths worldwide. …
Source: News from Mayo Clinic - August 13, 2022 Category: Databases & Libraries Source Type: news
New insights into the comorbid conditions of Turner syndrome: results from a long-term monocentric cohort study
ConclusionsThis cohort study confirms the need for continuous, structured and multidisciplinary lifelong monitoring of TS, thus ensuring the early diagnosis of important comorbid conditions, including cancer, and their appropriate and timely treatment. In addition, these data highlight the need for the increased surveillance of specific types of cancer in TS, including thyroid carcinoma.
Source: Journal of Endocrinological Investigation - July 30, 2022 Category: Endocrinology Source Type: research
Aging-Related Vascular Inflammation: Giant Cell Arteritis and Neurological Disorders
Front Aging Neurosci. 2022 Apr 12;14:843305. doi: 10.3389/fnagi.2022.843305. eCollection 2022.ABSTRACTAging is characterized by the functional decline of the immune system and constitutes the primary risk factor for infectious diseases, cardiovascular disorders, cancer, and neurodegenerative disorders. Blood vessels are immune-privileged sites and consist of endothelial cells, vascular smooth muscle cells, macrophages, dendritic cells, fibroblasts, and pericytes, among others. Aging also termed senescence inevitably affects blood vessels, making them vulnerable to inflammation. Atherosclerosis causes low-grade inflammation...
Source: Atherosclerosis - May 2, 2022 Category: Cardiology Authors: Ryu Watanabe Motomu Hashimoto Source Type: research
Prevalence and associated relating factors in patients with hereditary retinal dystrophy: a nationwide population-based study in Taiwan
CONCLUSIONS: 74% of the diagnosed HRD are retinitis pigmentosa. Population-based data suggested an increased incidence of cataract in younger patients, whereas older HRD patients are more susceptible to develop CME. Further work is needed to elucidate the mechanism between these ophthalmological disorders and HRD.PMID:35396285 | DOI:10.1136/bmjopen-2021-054111
Source: Cancer Control - April 9, 2022 Category: Cancer & Oncology Authors: Peng Yeong Woon Jia-Ying Chien Jen-Hung Wang Yu-Yau Chou Mei-Chen Lin Shun-Ping Huang Source Type: research
Immunomodulatory Therapeutic Effects of Curcumin on M1 / M2 Macrophage polarization in Inflammatory Diseases
CONCLUSION: Curcumin not only enhances anti- tumor immunity (via shifting M polarization towards to M1 phenotype and/or up-regulation of M1 markers expression), but ameliorates inflammatory diseases including auto immune diseases (experimental autoimmune myocarditis and Behcet's disease), nephropathy, chronic serum sickness, stroke and atherosclerosis.PMID:35331128 | DOI:10.2174/1874467215666220324114624
Source: Atherosclerosis - March 25, 2022 Category: Cardiology Authors: Elham Abdollahi Thomas P Johnston Zahra Ghaneifar Parviz Vahedi Pouya Goleij Sara Azhdari Abbas Shapouri Moghaddam Source Type: research
Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Prevalence and economic burden of major comorbidities in multiple sclerosis
ConclusionsOur study provides evidence of the burden of comorbidities in MS. Comorbidity is common in MS and produce additive costs.Key messagesThe use of administrative data for tracking the MS comorbidity could help knowledge gaps.When additivity situation is involved, preventive policies could lead to monetary savings.
Source: The European Journal of Public Health - October 20, 2021 Category: General Medicine Source Type: research
Thrombotic Thrombocytopenic Purpura Without Schistocytes: Beware of Misdiagnosis
A 43-year-old woman was admitted for acute unusual headache, vertigo, and left upper limb weakness. She had been complaining of asthenia for the past few weeks. Her medical history included uterine cervix cancer treated with conisation and 2 pregnancies without serious complications. No allergy or recent drug introduction was noted. After ruling out current pregnancy, magnetic resonance imaging (MRI) was immediately performed and showed recent ischemic strokes in multiple territories. Doppler ultrasound imaging showed no carotid or vertebral arteries lesion. Electrocardiogram showed no ST elevation or atrial fibrillation, ...
Source: Neurology Clinical Practice - October 11, 2021 Category: Neurology Authors: Decker, P., Moulinet, T., Revuz, S., Perez, P., Jaussaud, R. Tags: Autoimmune diseases, Hematologic, All Cerebrovascular disease/Stroke Case Source Type: research
Complications of Hepatocellular Carcinoma patients post living Donor Liver Transplantation
ConclusionThere was no statistical significance for those within or out side the Milan criteria or UCSF criteria and its impact on the occurrence of graft rejection, sepsis, vascular complications, death, HCC recurrence and biliary complications post-transplant.
Source: QJM - October 1, 2021 Category: Internal Medicine Source Type: research
Janssen Announces U.S. FDA Approval of PONVORY ™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions
TITUSVILLE, N.J. – (March 19, 2021) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.1,2,3 PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven safety profile backed by ove...
Source: Johnson and Johnson - March 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
